drugset

drugset / Trial / NCT00036556

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

NCT00036556 ↗

Phase 3 Completed 941 enrolled Abbott

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

Timeline

Start: 2001-06
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atrasentan	Other / unclassified	—	—

Indications